Shire now operates in 28 countries and this is set to grow further in 2010.
A story of continuing transformation
Robust intellectual property
Our strategy is for robust intellectual property and long market exclusivity.
A story of continuing transformation
Balanced portfolio
We have a balanced portfolio of products, covering a range of specialist treatments.
A story of continuing transformation
Technology platforms
Our three technology platforms are state of the art in their development to ensure we provide patients with the best treatment possible.
A story of continuing transformation
Strong pipeline
We have a good pipeline of products coming through over the next few years, with four in Phase 2 and five in Phase 3 clinical trials.
The quick read
How has Shire changed over the last five years? What was once the 'ADHD company' has now become one of the world's most successful specialty biopharmaceutical companies. An operation covering only nine markets now extends to 28, with more coming soon. A pipeline with great potential has become one that's delivering solid results, and a narrow research focus has expanded into leading-edge expertise in pioneering technologies like human cell line biologics and Carrierwave technology.
